LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Certara Inc

Gesloten

SectorGezondheidszorg

8.14 -2.16

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.09

Max

8.3

Belangrijke statistieken

By Trading Economics

Inkomsten

3.5M

1.5M

Verkoop

46K

105M

K/W

Sectorgemiddelde

123.143

105.69

EPS

0.14

Winstmarge

1.458

Werknemers

1,487

EBITDA

-21M

8.7M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+64.59% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-506M

1.4B

Vorige openingsprijs

10.3

Vorige sluitingsprijs

8.14

Nieuwssentiment

By Acuity

94%

6%

358 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Certara Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 nov 2025, 18:59 UTC

Belangrijke Marktbewegers

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov 2025, 23:40 UTC

Marktinformatie

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov 2025, 23:34 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov 2025, 22:58 UTC

Marktinformatie

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov 2025, 22:46 UTC

Marktinformatie

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 nov 2025, 21:40 UTC

Winsten

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov 2025, 21:40 UTC

Winsten

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov 2025, 21:39 UTC

Winsten

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov 2025, 21:38 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 21:38 UTC

Winsten

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov 2025, 21:10 UTC

Winsten

XP Inc. 3Q EPS BRL2.47 >XP

17 nov 2025, 21:10 UTC

Winsten

XP Inc. 3Q Rev BRL4.67B >XP

17 nov 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov 2025, 20:12 UTC

Marktinformatie

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov 2025, 20:12 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 nov 2025, 20:09 UTC

Marktinformatie

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov 2025, 19:29 UTC

Marktinformatie

Gold Slide Continues to Start Week -- Market Talk

17 nov 2025, 19:16 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 18:20 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov 2025, 16:45 UTC

Acquisities, Fusies, Overnames

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov 2025, 16:16 UTC

Winsten
Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 16:15 UTC

Winsten

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov 2025, 15:40 UTC

Acquisities, Fusies, Overnames

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov 2025, 15:22 UTC

Acquisities, Fusies, Overnames

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov 2025, 15:19 UTC

Marktinformatie

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer Vergelijking

Prijswijziging

Certara Inc Prognose

Koersdoel

By TipRanks

64.59% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.71 USD  64.59%

Hoogste 16 USD

Laagste 9 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Certara Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

4

Buy

5

Hold

0

Sell

Technische score

By Trading Central

11.27 / 12.79Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

358 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat